Quest Diagnostics Incorporated (DGX) is a prominent player in the diagnostic testing and information services industry, with a market cap of $19.3 billion. The company offers a wide range of clinical testing services to healthcare providers, patients, and organizations both in the United States and internationally. Operating under well-known brands such as Quest Diagnostics, AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum, Quest Diagnostics has built a strong reputation for delivering high-quality services through its extensive network of laboratories and healthcare professionals.
As Quest Diagnostics prepares to announce its fiscal Q4 2025 results, analysts are optimistic about the company’s performance. It is expected to report an adjusted EPS of $2.36, reflecting a 5.8% increase from the year-ago quarter. The company has a track record of surpassing Wall Street’s bottom-line estimates in previous quarterly reports. Looking ahead to fiscal 2025, analysts project a further rise in adjusted EPS to $9.79, a 9.6% increase from the previous fiscal year.
Despite the positive outlook, Quest Diagnostics’ stock performance has been somewhat mixed. Over the past 52 weeks, the company’s shares have increased by 15.1%, slightly trailing behind the S&P 500 Index’s 16.9% rise. However, Quest Diagnostics has outperformed the State Street Health Care Select Sector SPDR ETF, which saw a 13% gain over the same period.
In its most recent earnings report for Q3 2025, Quest Diagnostics exceeded expectations with adjusted EPS of $2.60 and revenue of $2.82 billion. The quarter demonstrated strong momentum, with significant year-over-year revenue growth and an increase in adjusted EPS. The company also raised its full-year 2025 guidance, projecting adjusted EPS in the range of $9.76 to $9.84. Despite the positive results, Quest Diagnostics’ stock experienced a slight dip of over 3% on the day of the earnings release.
Analysts maintain a cautiously optimistic outlook on DGX stock, with a consensus rating of “Moderate Buy.” Among the 18 analysts covering the stock, eight recommend a “Strong Buy” while 10 suggest a “Hold” rating. The average analyst price target for Quest Diagnostics is $199.47, indicating a potential upside of 14.8% from the current levels.
In conclusion, Quest Diagnostics continues to be a key player in the diagnostic testing industry, with a strong track record of performance and a positive outlook for future growth. Investors and analysts alike are keeping a close eye on the company’s upcoming earnings announcement and its potential impact on the stock’s performance.
